

REMARKS

The specification has been amended to reflect national stage status.

Claims 1-3, 5, 10, 14, 17, 22, 27 and 32 are amended to replace the phrase "a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 2, a functionally equivalent modified polypeptide thereof, or a polypeptide consisting of an amino acid sequence having 70% or more homology to the amino acid sequence of a polypeptide comprising the amino acid sequence represented by SEQ ID NO: 2" with "Relaxin-3." Support for this amendment can be found in the disclosure, for example, at page 15, line 10-26.

Claim 2 is revised to recite "An agent" to better conform with US practice and English form.


No new matter has been added.

Claims 1-52 are pending upon entry of this amendment.

Favorable action on the merits is solicited.

Respectfully submitted,

Takayuki HIDA et al.

By: 
Jay F. Williams
Registration No. 48,036
Attorney for Applicants

JFW/mjw
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
May 16, 2007